

1 **In utero human cytomegalovirus infection expands NK cell-like FcγRIII-expressing CD8+ T cells**
2 **that mediate antibody-dependent functions**

3

4 Authors: Eleanor C. Semmes^{1,2,3}, Danielle R. Netter^{1,2,4}, Ashley N. Nelson^{3,5}, Jillian H. Hurst^{5,6}, Derek
5 Cain³, Trevor D. Burt^{5,7}, Joanne Kurtzberg^{5,8}, Keith Reeves^{4,9,10}, Carolyn B. Coyne^{2,3,10,11}, Genevieve
6 Fouda^{3,5,12}, Justin Pollara^{3,4}, Sallie R. Permar^{3,5,12*}, Kyle M. Walsh^{5,13*†}

7

8 Affiliations

9 ¹ Medical Scientist Training Program, Duke University, Durham, NC, USA

10 ² Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA

11 ³ Duke Human Vaccine Institute, Duke University, Durham, NC, USA

12 ⁴ Department of Surgery, Duke University School of Medicine, Durham, NC, USA

13 ⁵ Children's Health and Discovery Initiative, Department of Pediatrics, Duke University, Durham, NC,
14 USA

15 ⁶ Division of Infectious Diseases, Department of Pediatrics, Duke University, Durham, NC, USA

16 ⁷ Division of Neonatology, Department of Pediatrics, Duke University, Durham, NC, USA (Trevor)

17 ⁸ Carolinas Cord Blood Bank, Marcus Center for Cellular Cures, Durham, NC, 27705 USA

18 ⁹ Division of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke
19 University, Durham, NC, USA

20 ¹⁰ Department of Pathology, Duke University School of Medicine, Durham, NC, USA

21 ¹¹ Department of Integrative Immunobiology, Duke University, Durham, NC, USA

22 ¹² Department of Pediatrics, Weill Cornell Medicine, New York City, NY, USA


23 ¹³ Department of Neurosurgery, Duke University, Durham, NC, USA[‡]

* Co-senior authors. Correspondence: sallie.permar@med.cornell.edu (SRP) and kyle.walsh@duke.edu (KMW)

† Lead contact

24 **Abstract**

25 Human cytomegalovirus (HCMV) profoundly modulates host T and natural killer (NK) cells across the
26 lifespan, expanding unique effector cells bridging innate and adaptive immunity. Though HCMV is the
27 most common congenital infection worldwide, how this ubiquitous herpesvirus impacts developing fetal
28 T and NK cells remains unclear. Using computational flow cytometry and transcriptome profiling of cord
29 blood from neonates with and without congenital HCMV (cCMV) infection, we identify major shifts in fetal
30 cellular immunity marked by an expansion of Fcγ receptor III (FcγRIII)-expressing CD8⁺ T cells (FcRT)
31 following HCMV exposure in utero. FcRT cells from cCMV-infected neonates express a cytotoxic NK cell-
32 like transcriptome and mediate antigen-specific antibody-dependent functions including degranulation
33 and IFN γ production, the hallmarks of NK cell antibody-dependent cellular cytotoxicity (ADCC). FcRT
34 cells may represent a previously unappreciated effector population with innate-like functions that could
35 be harnessed for maternal-infant vaccination strategies and antibody-based therapeutics in early life.



36

37 **Keywords:** CMV, cytomegalovirus, congenital infection, fetal immunity, innate-like T cells, CD8⁺ T cells,
38 adaptive NK cells, Fc receptor, Fc effector function, ADCC

39 Introduction

40 Human cytomegalovirus (HCMV) is a ubiquitous β -herpesvirus that has co-evolved with humans
41 over millennia and is an important member of the human virome, a dynamic network of commensal and
42 pathogenic viruses (Cadwell, 2015; Davis and Brodin, 2018). Globally, greater than 80% of individuals
43 are latently infected with HCMV (Zuhair et al., 2019) and few human pathogens are known to exert such
44 a profound imprint on host immunity across the lifespan (Brodin et al., 2015). While primary infection,
45 latency reactivation, and reinfection are usually asymptomatic in healthy children and adults, HCMV can
46 cause severe disease in immunocompromised populations including fetuses, transplant recipients, and
47 persons living with HIV/AIDS. HCMV is the most common vertically transmitted infection worldwide and
48 can cause devastating neurologic disease, yet the majority of infants born with HCMV or infected
49 postnatally are asymptomatic (Boppana et al., 2013). Latent HCMV infection in healthy children and
50 young adults may even enhance heterologous immune responses to infections and vaccines (Davis and
51 Brodin, 2018; Furman et al., 2015; Semmes et al., 2020b). Thus, while HCMV remains a significant
52 pathogen for prenatal and immunocompromised populations, emerging evidence suggests that HCMV
53 may enhance host immunity in young, healthy individuals.

54 HCMV infection shapes global immune cell profiles, not just HCMV-specific cells, creating long-
55 lasting shifts in natural killer (NK) and T cell compartments and expanding unique effector populations
56 bridging innate and adaptive immunity (Brodin *et al.*, 2015; Rolle and Brodin, 2016). “Memory-like” or
57 “adaptive” NK cells generated by interactions between the HCMV peptide UL40 and NKG2 killer lectin-
58 like (KLR) receptors are persistently expanded in HCMV-infected individuals and can mediate enhanced
59 anti-viral responses upon restimulation (Guma et al., 2004; Schlums et al., 2015) . Additionally, HCMV
60 seropositivity has been associated with a dramatic clonal expansion of HCMV-specific CD8+ T cells and
61 with the activation and terminal differentiation of bystander non-HCMV specific CD8+ T cells (Almanzar
62 et al., 2005; Sylwester et al., 2005). Mature CD8+ T cell subsets that express NK receptors including Fcy
63 receptor III (FcyRIII, also known as CD16), NKG2C, and killer-like immunoglobulin receptors (KIRs) that
64 demonstrate hybrid T-NK cell functions have also been observed in adults with chronic HCMV infection
65 (Remmerswaal et al., 2019; Sottile et al., 2021).

66 Despite HCMV's significant impact on the adult immune system, our understanding of how HCMV
67 modulates NK and T cells in early life is limited. Fetal HCMV-specific CD8⁺ and CD4⁺ T cells and
68 restricted $\gamma\delta$ T cell subsets can expand following infection (Antoine et al., 2012; Huygens et al., 2014;
69 Huygens et al., 2015; Marchant et al., 2003; Vermijlen et al., 2010), but the global impact of HCMV on
70 developing T cells is unknown. Vaaben et al. recently reported that fetal NK cells from infants with cCMV
71 infection highly express markers of maturation, activation, and cytotoxicity (Vaaben et al., 2022), yet the
72 functional capacity of these NK cells and whether adaptive-like NK cell subsets are generated in utero
73 remains unclear (Vaaben *et al.*, 2022). Importantly, the fetal and neonatal immune landscape is
74 fundamentally distinct from the adult immune system, as it is relatively biased towards immunotolerance
75 and innate immune responses (Kollmann et al., 2017; Semmes et al., 2020a), leading us to question how
76 HCMV exposure in utero influences developing T and NK cells.

77 In this study, we investigated how HCMV impacts fetal T and NK cell populations using banked
78 cord blood from U.S. donors with and without cCMV infection. We comprehensively characterized cord
79 blood T and NK cells using multiparameter flow cytometry, whole transcriptome profiling, and functional
80 assays, and identified a striking expansion of a population of CD8⁺ T cells expressing NK cell associated
81 markers, including Fc γ RIII, in cCMV-infected neonates. Fc γ RIII⁺CD8⁺ T cells (which we refer to as FcRT
82 cells) expressed an NK-like transcriptional profile and mediated robust antibody-dependent functions.
83 These findings suggest that fetal CD8⁺ T cells can be stimulated to differentiate into innate-like cells that
84 mediate antibody-dependent cellular cytotoxicity (ADCC), an Fc effector function traditionally associated
85 with NK cells. FcRT cells may have promising translational potential as a novel effector cell population
86 linking innate and adaptive immunity that could be harnessed by vaccines and antibody-based
87 therapeutics in early life.

88 **Results**

89

90 **Cord blood donor immunophenotyping data highlights distinct immune landscape in cCMV-**
91 **infected versus uninfected neonates**

92 In this study, we analyzed umbilical cord blood from the U.S.-based Carolinas Cord Blood Bank
93 (CCBB), an FDA licensed (DUCORD), public cord blood bank housed at Duke University. In the CCBB
94 donor database, we retrospectively identified 59 cases of cCMV infection (based on screening for cord
95 blood HCMV DNAemia) with banked biospecimens and phenotyping data available (**Supplementary**
96 **Fig. 1**). Using infant sex, race/ethnicity, maternal age, and delivery year as matching variables, cCMV-
97 infected neonates were matched to at least two control donors without cCMV infection. Demographic and
98 clinical characteristics were similar between cCMV-infected (cCMV+; n=59) and uninfected (cCMV-;
99 n=135) donors (**Supplementary Table 1**).

100 First, we analyzed cord blood donor immunophenotyping data from the CCBB donor database to
101 identify differences between cCMV+ and cCMV- cord blood units. Total numbers and proportions of
102 hematopoietic stem cells (CD34+), mature leukocytes (CD45+), and major immune cell lineages including
103 18 total immune parameters were available for analyses. There was a significant lymphocytosis in the
104 cord blood of cCMV+ versus cCMV- neonates ($P < 0.0001$, **Fig. 1A**), characterized by a higher proportion
105 of CD3+ T cells in cCMV+ neonates ($P < 0.0001$, **Fig. 1B**). The ratio of CD4+/CD8+ T cells was decreased
106 in cCMV+ versus cCMV- neonates ($P < 0.0001$), driven by an expansion of CD8+ T cells (**Fig. 1C-E**). To
107 a lesser degree, CD4-CD8- “double negative” T cells (**Fig. 1F**) and NK cells (**Fig. 1G**) were also expanded
108 in cCMV+ neonates. Next, we used principal components analysis (PCA) to visualize the cord blood
109 immunophenotyping data by cCMV status. Together, PC1 and PC2 accounted for ~50% of the total
110 variance between donors (**Fig. 1H**). Cord blood immunophenotypes from cCMV+ and cCMV- neonates
111 clustered distinctly (**Fig. 1H**), with increased CD8+ T cells as the top parameter associated with cCMV
112 infection (**Fig. 1I**). We also visualized the PCA by infant sex, infant race/ethnicity, and delivery mode and
113 found no evidence that these characteristics were underlying differences in cord blood immune profiles

114 **(Supplementary Fig. 2).** Overall, these data indicate that HCMV stimulates the expansion of fetal innate
115 (i.e., NK cells) and adaptive (i.e., CD8+ T cells) populations.

116

117 **CD56^{neg}CD16/FcγRIII⁺ and NKG2C⁺ NK cells expand in cord blood from cCMV-infected versus**
118 **uninfected neonates**

119 To explore how HCMV exposure in utero influences host immune cell compartments, we
120 performed multiparameter flow cytometry and transcriptional profiling of NK and T cells in an available
121 subset of cord blood samples from cCMV+ (n=21) and cCMV- (n=20) neonates. Total NK cells and 3
122 major NK cell subsets including CD56^{neg}CD16⁺, CD56^{bright}CD16^{+/-}, and CD56^{dim}CD16^{+/-} NK cells (Ty et al.,
123 2023; Vaaben *et al.*, 2022) were compared in cCMV+ versus cCMV- neonates (**Fig. 2A**). CD56^{neg}CD16⁺
124 NK cells were significantly expanded (**Fig. 2B**) in cCMV+ infants, and both CD56^{neg}CD16⁺ and
125 CD56^{bright}CD16^{+/-} NK cells had higher expression of the activation and differentiation marker CD57 (**Fig.**
126 **2C**). NKG2C, but not NKG2A, was also more frequently expressed on NK cells from cCMV+ versus
127 cCMV- neonates (**Fig. 2D-E**). Expression of NKG2C and CD57 are both hallmarks of the adaptive NK
128 cell subsets expanded in adults with chronic HCMV infection (Rolle and Brodin, 2016). Next, we
129 performed RNA sequencing of FAC-sorted total NK cells (n=13 cCMV+, n=12 cCMV-). Differential gene
130 expression analysis identified 75 upregulated and 77 downregulated genes in NK cells from cCMV+
131 versus cCMV- groups (**Fig. 2F-G**) with enriched gene ontology pathways including innate immune
132 response ($P_{adj} = 1.0 \times 10^{-4}$), defense response to virus ($P_{adj} = 2.5 \times 10^{-4}$), and type I interferon signaling (P_{adj}
133 $= 6.7 \times 10^{-4}$). Expression of LAG3, a checkpoint inhibitor induced by type I IFN that is highly expressed on
134 ADCC-mediating CD56^{neg}CD16⁺ NK cells (Ty *et al.*, 2023), was 4-fold higher in NK cells from cCMV+
135 versus cCMV- neonates ($P_{FDR} = 2.53 \times 10^{-10}$). JAKMIP1, a marker of adaptive NK cells in chronic HCMV
136 infection (Rückert *et al.*, 2022) was also elevated 5-fold ($P_{FDR} = 2.53 \times 10^{-3}$). Together, these data
137 demonstrate that NK cells with an anti-viral transcriptional program and adaptive phenotype expand in
138 utero following HCMV infection.

139

140 **CD8+ T cells upregulate cytotoxic molecules and NK cell associated genes in cord blood from**
141 **cCMV-infected versus uninfected neonates**

142 Next, we compared CD4+ and CD8+ T cells in cord blood from cCMV+ (n=21) and CMV- (n=20)
143 neonates. There were no differences in the proportions of naïve, central memory (Tcm), effector memory
144 (Tem), terminally differentiated effector memory T cells re-expressing CD45RA+ (Temra), or regulatory
145 (Treg) CD4+ T cell subsets between cCMV+ and cCMV- neonates (**Supplementary Fig. 3A-B**). The
146 frequency of CD4+ T cells expressing activation (HLA-DR, CD57), differentiation (CD57), and antigen
147 stimulation (PD-1) markers were higher in cCMV+ infants, but these subsets were low frequency overall
148 (**Supplementary Fig. 3C**). Differential gene expression analysis identified 180 upregulated and 368
149 downregulated genes in CD4+ T cells from cCMV+ (n=11) versus cCMV- (n=12) neonates
150 (**Supplementary Fig. 3D**), yet only 25 genes remained significantly enriched after false discovery rate
151 (FDR) correction ($P_{\text{FDR}} < 0.01$) for multiple comparisons (**Supplementary Fig. 3E**). Expression of CCL5
152 ($P_{\text{FDR}} = 1.10 \times 10^{-8}$), a proinflammatory chemokine that recruits T and NK cells, and natural-killer gene 7
153 (NKG7, $P_{\text{FDR}} = 1.97 \times 10^{-6}$), which helps traffic cytotoxic vesicles to the immunological synapse were
154 induced 5-fold (**Supplementary Fig. 3D-E**). Transcripts for cytolytic molecules granzyme H and
155 granzyme B were also upregulated 7-fold ($P_{\text{FDR}} = 5.8 \times 10^{-6}$) and 5-fold ($P_{\text{FDR}} = 0.01$) respectively
156 (**Supplementary Fig. 3D-E**). Taken together, these data suggest that HCMV activates a minor subset of
157 fetal CD4+ T cells, particularly those with cytotoxic activity or function in the recruitment of cytotoxic cells.

158 In contrast to the moderate changes in CD4+ T cells, we observed profound differences in the
159 CD8+ T cell compartment. Proportions of Tcm and Tem CD8+ T cells were increased, whereas naïve
160 CD8+ T cells were decreased in cCMV+ neonates (**Fig. 3A**). CD57 was expressed on most CD8+ T cells
161 from cCMV+ (median = 59.4%) versus <1% of CMV- infants (**Fig. 3B**). Differential gene expression
162 analysis from whole transcriptome sequencing identified 774 upregulated and 420 downregulated genes
163 in CD8+ T cells from cCMV+ (n=13) versus cCMV- (n=11) groups (**Fig. 3C-D**). Multiple proinflammatory
164 chemokines including CCL3 ($P_{\text{FDR}} = 1.1 \times 10^{-18}$), CCL4 ($P_{\text{FDR}} = 2.1 \times 10^{-30}$), and CCL5 ($P_{\text{FDR}} = 1.7 \times 10^{-20}$)
165 were upregulated (**Fig. 3D**). Gene expression of cytolytic molecules granzyme H ($P_{\text{FDR}} = 1.6 \times 10^{-11}$),
166 granzyme B ($P_{\text{FDR}} = 3.8 \times 10^{-18}$), perforin ($P_{\text{FDR}} = 9.2 \times 10^{-12}$), granulysin ($P_{\text{FDR}} = 2.7 \times 10^{-14}$) and NKG7 (P_{FDR}

167 = 1.5×10^{-24}) were increased 3-to-5-fold in cCMV+ versus cCMV- infants (**Fig. 3C-F**). Expression of
168 transcripts encoding FcγRIIIa/CD16A ($\text{Log}_2\text{FC} = 5.9$, $P_{\text{FDR}} = 8.8 \times 10^{-26}$), FcγRIIIb/CD16B ($\text{Log}_2\text{FC} = 6.9$,
169 $P_{\text{FDR}} = 1.7 \times 10^{-13}$), and killer cell lectin-like receptors (KLR) were also markedly increased in CD8+ T cells
170 from cCMV+ neonates (**Fig. 3. C-D, F**). Gene set enrichment analysis (GSEA) demonstrated that the top
171 induced pathways in CD8+ T cells from cCMV+ versus cCMV- infants included NK cell mediated immunity
172 ($P_{\text{adj}} = 1.3 \times 10^{-3}$), NK cell mediated cytotoxicity ($P_{\text{adj}} = 1.3 \times 10^{-3}$), and regulation of NK cell mediated
173 immunity ($P_{\text{adj}} = 2.9 \times 10^{-3}$) (**Supplementary Table 2**). Together, these data indicate that fetal CD8+ T
174 cells exposed to HCMV in utero have high cytotoxic potential and upregulate NK cell associated genes
175 that may contribute to unique anti-viral functions.

176

177 **CD8+ T cells expressing FcγRIII and NKG2A/C expand in cord blood from cCMV-infected versus** 178 **uninfected neonates**

179 To further define CD8+ T cell populations expressing NK cell markers, we analyzed our flow
180 cytometry data using a machine learning algorithm called CITRUS (cluster identification, characterization,
181 and regression). CITRUS uses unsupervised hierarchical clustering of multiparameter flow cytometry
182 data instead of manual gating to identify immune cell populations that differ between groups (Bruggner
183 et al., 2014). We first used t-SNE-CUDA (Chan et al., 2019) to visualize our 16-color single cell data (**Fig.**
184 **4A**) and select fluorescent channels for downstream analysis. CD3, CD4, CD8, CD127, CD25, CD19,
185 CD56, FcγRIII/CD16, NKG2A, NKG2C, HLA-DR, and CD14 marker expression on 1,250,000 cells
186 (50,000 cells/sample, $n = 25$, minimum cluster size = 1,250 cells) were used to generate the CITRUS
187 cluster map (**Fig. 4B, Supplementary Fig. 4**). CITRUS identified 38 immune cell clusters that differed
188 significantly ($P_{\text{FDR}} < 0.01$) between cCMV+ and cCMV- groups, including multiple clusters of activated
189 CD8+ and CD4+ T cells that we previously identified with manual gating (**Fig. 4B**). Two clusters in the
190 CD8+ T cell “branch”, one co-expressing NKG2A and NKG2C (**Fig. 4C**) and the other co-expressing
191 FcγRIII and NKG2C (**Fig. 4D**), were also significantly expanded in cCMV+ versus cCMV- cord blood.
192 These populations clustered distinctly from the NK cell “branch” (**Fig. 4B**) and had high expression of the
193 T cell lineage marker CD3 (**Fig. 4C-D**). Using manual gating (**Fig. 4E**), we confirmed that CD8+ T cells

194 expressing FcγRIII were significantly increased in cord blood from cCMV+ (median = 11.2%) versus
195 cCMV- (median = 2.2%) neonates (**Fig. 4F**). The frequency of CD8+ T cells expressing NKG2A and
196 NKG2C was also increased in cCMV+ infants and nearly absent (median <1%) in cCMV- infants (**Fig.**
197 **4F**). Together, these data demonstrate that CD8+ T cells expressing the NK cell associated receptors
198 FcγRIII and NKG2A/C expand following HCMV exposure in utero.

199

200 **FcγRIII+CD8+ T (FcRT) cells in cord blood from cCMV-infected neonates are a heterogenous** 201 **population expressing activation and terminal differentiation markers**

202 CD8+ T cells expressing NK cell markers have been described as a differentiated cell subset with
203 NK-like functions in adults with chronic viral infections including HCMV, EBV, HIV and HCV (Björkström
204 et al., 2008; Clémenceau et al., 2008; Mazzarino et al., 2005; Naluyima et al., 2019; Pietra et al., 2003).
205 To further characterize these cells in cord blood, we designed a 14-color panel with select T and NK cell
206 markers based on this prior literature. CITRUS analysis of CD3, CD4, CD8, CD56, FcγRIII (CD16), γδ
207 TCR, CCR7, CD45RA, PD-1, CD57, NKG2A, and NKG2C marker expression on 1,200,000 cells (75,000
208 cells/sample, n=16 samples, minimum cluster size = 1,200 cells) generated a cluster map with distinct
209 “branches” of T and NK cell clusters and identified 28 clusters that differed significantly ($P_{FDR} < 0.01$)
210 between cCMV+ (n=8) and cCMV- (n=8) groups (**Fig. 5A, Supplementary Fig. 5**). Multiple CD8+ T cell
211 clusters with increased FcγRIII expression were enriched in cCMV+ cord blood (**Fig. 5A, Supplementary**
212 **Fig. 5**). Most FcγRIII+CD8+ T cell clusters resembled canonical differentiated CD8+ T cells, whereas two
213 clusters expressed the γδ TCR and had variable expression of activation and differentiation markers (**Fig.**
214 **5B**). We next confirmed these differences by manual gating on FcγRIII+ and FcγRIII-CD8+ T cells. While
215 the majority of FcγRIII+CD8+ T cells did not express the γδ TCR, there was a higher frequency of γδ
216 TCR expression in the FcγRIII+ (median = 27%) versus FcγRIII-CD8+ T cell subsets (**Fig. 5C**).
217 FcγRIII+CD8+ T cells were more likely to be Temra than FcγRIII-CD8+ T cells (**Fig. 5D**). The majority of
218 FcγRIII+CD8+ T cells expressed CD57 (median = 77%) whereas PD-1 and NKG2A/C expression was
219 more variable (**Fig. 5D-E**). Together, these data suggest that FcγRIII+CD8+ T cells, which we refer to as

220 FcRT cells, are a heterogenous population of activated and terminally differentiated T cells that expand
221 in utero following HCMV infection.

222

223 **FcγRIII+CD8+ T (FcRT) cells in cord blood from cCMV-infected neonates upregulate a NK cell-like**
224 **antibody effector transcriptional program**

225 Next, we compared the whole transcriptome of FcRT and FcγRIII-CD8+ T cells from cCMV+ and
226 cCMV- neonates. Cytolytic molecules, chemotactic chemokines, and sphingosine-1-phosphate receptor
227 5 (S1PR5), which regulates T cell infiltration and migration, were upregulated in FcRT and FcγRIII-CD8+
228 T cells from cCMV+ infants (**Fig. 6A-B, Supplementary Fig. 6A-B**). FcγRIII-CD8+ T cells from cCMV-
229 infants had a distinct transcriptional profile compared to FcRT cells with increased expression of IL7R
230 and CCR7, genes associated with naïve T cells (**Fig. 6C-D**). FcγRIII-CD8+ T cells from cCMV+ infants
231 had an intermediate transcriptional profile that clustered between FcRT cells and FcγRIII-CD8+ T cells
232 from cCMV- infants (**Fig. 6C-E**). KIR and KLR gene expression was highly upregulated in FcRT cells
233 (**Fig. 6E, Supplementary Fig. 6C-D**) as were additional “NK cell identity” genes including CD244, NCR1,
234 NCAM1, TYROBP, and ITGAX that were preselected based on prior publications (Naluyima *et al.*, 2019;
235 Sottile *et al.*, 2021) (**Fig. 6E**). PCA of T and NK cells together further demonstrated that FcRT cells
236 acquire an NK-like transcriptional profile (**Fig. 7A**) with expression of cytotoxic molecules and FcγRs
237 approaching or exceeding NK cells (**Fig. 7B-C**). In contrast, FcγRIII-CD8+ T cells from cCMV+ infants
238 expressed a mixed transcriptional profile with variable induction of NK cell associated markers and FcγRs
239 (**Fig. 6E, Fig. 7A-C**). FCGR3A, which encodes FcγRIIIa/CD16A, was the most highly expressed FcγR in
240 FcRT cells; however, gene expression of FCGR3B (FcγRIIIb/CD16B), FCGR2B (FcγRIIb/CD32B), and
241 FCGR2C (FcγRIIIc/CD32C), which can mediate ADCC or other Fc effector functions, was also increased
242 (**Fig. 7C**). Together, these data demonstrate that FcRT cells in cCMV+ neonates acquire an NK cell-like
243 transcriptional profile with the potential capacity to execute antibody-mediated cytotoxic effector
244 functions.

245

246 **Cord blood NK and FcγRIII+CD8+ T (FcRT) cells produce IFNγ and degranulate against antibody-**
247 **opsonized target cells**

248 To assess whether FcRT cells can mediate Fc-dependent effector functions, we used cord blood
249 NK and CD8+ T cells to measure antibody-dependent degranulation and IFNγ production, which are key
250 markers of ADCC activity (**Fig. 8A**). Using intracellular staining, we confirmed our transcriptional data
251 showing higher protein expression of perforin and granzyme B in FcRT cells (**Fig. 8B**). The frequency of
252 FcRT cells containing perforin and granzyme B was high (median = 85.9%) and even exceeded
253 autologous NK cells (median = 73%) from cCMV+ neonates (**Fig. 8B**). To test FcγR function, we
254 employed a previously-established assay for assessing NK cell ADCC activity (Chung et al., 2009). We
255 used an HIV model system, as all donors previously screened HIV negative, ensuring responses to the
256 challenge antigen were antibody-mediated and not influenced by memory T cell responses. First, we
257 measured NK cell degranulation and IFNγ production in response to antibody stimulation, which was
258 comparable in cord blood from cCMV+ and cCMV- neonates (**Fig. 8C-D**). Both markers of ADCC activity
259 were enhanced when NK cells were preincubated with IL-15 (**Fig. 8C-D**), consistent with prior literature
260 indicating that IL-15 augments neonatal NK cell cytotoxicity (Pollara et al., 2020). Next, we assessed the
261 capacity of cord blood CD8+ T cells to mediate Fc-dependent antibody effector functions. FcγRIII-CD8+
262 T cells from cCMV+ and cCMV- infants did not degranulate or produce effector cytokines against HIV
263 antigen coated cells when co-incubated with non-specific or HIV-specific antibodies (**Fig. 8E-H**). In
264 contrast, FcRT cells from cCMV+ neonates were able to degranulate, as measured by CD107a
265 expression, and produce IFNγ in an antigen-specific antibody-dependent manner (**Fig. 8E-H**). Moreover,
266 FcRT cells demonstrated increased degranulation and IFNγ production if preincubated with IL-15 (**Fig.**
267 **8E-H**), similar to autologous NK cells (**Fig. 8C-D**). Altogether, these data demonstrate that cord blood
268 FcRT cells as well as NK cells can mediate robust ADCC-associated antibody-dependent functions that
269 are enhanced by effector cytokines.

270

271 Discussion

272 Congenital infections like HCMV pose a unique challenge to the developing immune system,
273 which must balance the competing demands of anti-pathogen defense versus immunotolerance to
274 maternal alloantigens, commensal microbiota, and environmental antigens (Kollmann *et al.*, 2017). As
275 such, fetal and neonatal immune cells favor innate over adaptive responses (Galindo-Albarrán *et al.*,
276 2016; Semmes *et al.*, 2020a) and antigen-specific responses by newly generated T and B cells remain
277 limited. While HCMV-specific T cells have been observed in cord blood from cCMV+ infants, these
278 adaptive T cell responses against HCMV are constrained by functional exhaustion acquired in utero
279 (Antoine *et al.*, 2012; Huygens *et al.*, 2014; Huygens *et al.*, 2015). Here, we demonstrate that cord blood
280 CD8+ T cells acquire an NK-like phenotype and mediate innate effector functions through FcγRIII
281 following HCMV exposure in utero. These results identify an alternative pathway by which the developing
282 immune system can overcome the limitations to adaptive immunity in early life by engaging CD8+ T cells
283 in Fc-mediated immunity. We show that FcγRIII+CD8+ T cells (which we refer to as FcRT cells) and NK
284 cells in cord blood from cCMV-infected neonates respond robustly to antibody stimulation via
285 degranulation and IFN γ production, indicating that both FcRT and NK cells are poised to mediate ADCC.
286 That FcRT cells highly expressed granzyme, perforin, and granulysin and NKG-7, which facilitates
287 cytotoxic granule exocytosis and enhances NK and CD8+ T cell cytotoxicity (Malarkannan, 2020; Ng *et al.*,
288 2020), underscores the cytotoxic potential of these cells. Altogether, our work suggests that FcγRIII-
289 expressing T and NK cells can bridge innate and adaptive immunity through Fc-mediated antibody
290 functions and may contribute to host defense during early infant immune development.

291 NK-like CD8+ T cells have been described in adults with chronic viral infections including HIV
292 (Naluyima *et al.*, 2019; Phaahla *et al.*, 2019), HCV (Björkström *et al.*, 2008), EBV (Clémenceau *et al.*,
293 2008), and HCMV (Mazzarino *et al.*, 2005; Pietra *et al.*, 2003; Sottile *et al.*, 2021). These NK-like CD8+
294 T cells do not fit the characteristics of iNKT or canonical $\gamma\delta$ T cells, but rather represent separate
295 heterogenous subpopulations of innate-like T cells (Koh *et al.*, 2023). Other groups have described
296 FcγRIII-expressing CD8+ T cells in adults that can mediate ADCC (Björkström *et al.*, 2008; Clémenceau
297 *et al.*, 2008; Naluyima *et al.*, 2019), which can be further enhanced by IL-15 (Choi *et al.*, 2023). Our study

298 demonstrates that FcRT cells with a similar transcriptional profile, cytokine responsiveness, and
299 functionality can be induced in an immature, developing immune system. Given the limited gestational
300 window in which these infections can occur, our identification of these NK-like CD8+ T cells in cord blood
301 challenges the assumption that these cells develop over months to years following chronic antigenic
302 stimulation (Koh *et al.*, 2023). Our findings indicate that this may be a more conserved and fundamental
303 pathway for T cells to take given the ability of developing fetal T cells to acquire these transcriptional
304 changes and functions in early life. That the fetal immune system can rapidly develop NK-like CD8+ T
305 cells in response to an infectious stimulus suggests that neither chronic infection nor a fully developed
306 adult immune system is required to generate these populations. Our work reveals that FcRT cells may
307 be a previously unappreciated effector cell population present in early life that could contribute to host
308 defense by acquiring antibody effector functions.

309 Our study also identified minor, but notable, changes in the NK cell compartment following cCMV
310 infection. Some cord blood samples from cCMV-infected neonates had an expansion of NKG2C+ NK
311 cells, which is a marker for the adaptive NK cells associated with chronic HCMV infection in adults and
312 children (Guma *et al.*, 2004; Guma *et al.*, 2006; Monsivais-Urenda *et al.*, 2010; Noyola *et al.*, 2012).
313 Because this process is driven by epigenetic reprogramming following repeated antigenic stimulation
314 (Lee *et al.*, 2015; Schlums *et al.*, 2015), this may be a slower occurring adaptation, partially explaining
315 why it was not present in all cCMV+ neonates. Rather, a more consistent difference we identified between
316 cord blood from cCMV+ and cCMV- infants was the expansion of “atypical” or “adaptive-like” CD56neg
317 NK cells. Expansion of CD56neg NK cells, which are believed to function through FcγRIII-mediated
318 ADCC rather than direct cytotoxicity (Forconi *et al.*, 2018; Forconi *et al.*, 2020; Ty *et al.*, 2023), has been
319 observed in HCMV, EBV and malaria infection in early life (Forconi *et al.*, 2018; Ty *et al.*, 2023; Vaaben
320 *et al.*, 2022). CD56neg NK cells highly express CD57 and upregulate LAG3, mirroring the transcriptional
321 changes we observed in cCMV infection, but their functionality remains unclear. Our work suggests that
322 NK cells expanded following HCMV exposure in utero have the capacity to execute ADCC but whether
323 CD56neg NK cells aid in anti-viral control of HCMV via antibody-dependent mechanisms should be
324 explored in future studies (Semmes and Permar, 2022).

325 Our data provide important insights into the influence of cCMV infection on host cellular immunity
326 and also highlight an opportunity to protect neonates more broadly using antibody-based interventions
327 against infected, malignant, or autoimmune cells. Maternal IgG antibodies are actively transferred across
328 the placenta via FcγRs to protect infants from infectious diseases (Fouda et al., 2018; Jennewein et al.,
329 2017; Jennewein et al., 2019; Martinez et al., 2019). We speculate that FcRT cells may represent an
330 additional effector cell population that can expand the cellular compartment to leverage maternal IgG in
331 early life. Vaaben et al. recently proposed that FcγRIII-activating maternal IgG may synergize with
332 neonatal NK cells to protect against HCMV via antibody-dependent mechanisms (Semmes and Permar,
333 2022; Vaaben *et al.*, 2022), a hypothesis that our data further supports. We recently reported that higher
334 levels of FcγRIII and ADCC-activating IgG in maternal and cord blood sera were associated with
335 protection against fetal HCMV transmission in this same cohort (Semmes et al., 2023; Semmes et al.,
336 2022). Thomas et al. also found that higher ADCC-mediating antibody responses and viral susceptibility
337 to ADCC were associated with decreased risk of HIV-1 transmission in utero (Thomas et al., 2022).
338 Together, these findings suggest that Fc-mediated responses linking maternal and fetal immunity may
339 contribute to protection against congenital infections. We propose that both neonatal NK and FcRT cells
340 could be targeted with therapeutic monoclonal antibodies or vaccines designed to engage both the
341 maternal and infant immune systems.

342 There are several limitations to our study that could be expanded upon in future work. Our
343 retrospective cohort limited us from collecting additional clinical data and longitudinal biospecimens. As
344 such, we could not investigate how these changes in the cellular compartment relate to clinical outcomes
345 or whether the gestational timing of transmission influenced fetal FcRT or NK cell responses. Moreover,
346 we could not determine how long these changes in the cellular compartment persist and whether they
347 maintain functionality over time. Finally, banked cord blood sample volumes were limited, so we could
348 only perform functional studies on a subset of infants. Nevertheless, the data presented convincingly
349 demonstrate that cCMV infection expands a CD8⁺ T cell subset expressing a NK cell-like phenotype,
350 transcriptional profile, and functionality. Future studies should investigate how these immunological

351 changes relate to anti-viral control and clinical outcomes of cCMV infection and further characterize the
352 origin, persistence, and functions of FcRT cells in early life.

353 In conclusion, we have demonstrated that cCMV infection profoundly modulates developing T
354 and NK cell compartments, marked by the expansion of FcyRIII-expressing CD8⁺ T cells that have high
355 cytotoxic potential and respond robustly to antibody stimulation. The role of FcRT and NK cells in fetal
356 defense against congenital infections must be explored further, but both cell populations represent
357 promising translational targets to overcome the challenges to generating adaptive immune responses in
358 early life. Altogether, our work suggests that both FcRT and NK cells can mediate antibody effector
359 functions through FcyR engagement and could be harnessed by maternal-infant vaccination strategies
360 or antibody-based therapeutics to protect the infant against infectious diseases.

361 **Methods**

362

363 **Human umbilical cord blood samples**

364 Our study included cases of congenital cytomegalovirus infection (cCMV) and controls without cCMV
365 infection that were recruited from 2008-2017 as donors to the Carolinas Cord Blood Bank (CCBB).
366 Approval was obtained from Duke's Institutional Review Board (Pro00089256) to use de-identified clinical
367 data and biospecimens provided by the CCBB. No patients were prospectively recruited for this study
368 and all cord blood was acquired retrospectively from the CCBB biorepository from donors who provided
369 written consent for biospecimens to be used for research. Cases and controls were identified from over
370 29,000 CCBB donor records (see **Supplementary Fig. 1** for an overview of sample selection). Maternal
371 donors underwent infectious diseases screening for HCMV, hepatitis B virus, syphilis, hepatitis C virus,
372 HIV-1/2, HTLV I and II, Chagas Disease, and West Nile virus. Only donors with healthy, uncomplicated
373 pregnancies that gave birth at term were included and infants were screened for signs of (a) neonatal
374 sepsis, (b) congenital infection (petechial rash, thrombocytopenia, hepatosplenomegaly), and (c)
375 congenital abnormalities. Cord blood plasma was screened by the CCBB for HCMV viremia with a Real-
376 Time PCR COBAS AmpliPrep/TaqMan nucleic acid test (Roche Diagnostics). Cases of cCMV infection
377 were defined as donors with cord blood that screened positive for HCMV DNAemia per PCR. Cases with
378 cCMV infection (cCMV+, n=59) were matched to at least 2 uninfected controls (cCMV-, n=135) that did
379 not have detectable HCMV DNAemia in the cord blood at birth. Matching variables included infant sex,
380 race/ethnicity, maternal age (+/- 3 years), and delivery year (+/- 3 years), as reported in **Supplementary**
381 **Table 1**.

382

383 ***CCBB graft characterization***

384 Flow cytometry graft characterization was performed at the time of donation on fresh umbilical cord blood
385 mononuclear cells (CBMCs) by the Duke Stem Cell Transplant Laboratory of Duke University Hospital,
386 a CAP and FACT accredited, CLIA certified clinical laboratory which provides contract services to the

387 CCBB. Graft characterization data was then obtained retrospectively from the CCBB donor database.
388 PCA plots of graft characterization data were rendered using ggplot2 (v3.4.0) in R.

389

390 ***NK and T cell phenotyping and sorting***

391 Flow cytometry was performed in the Duke Human Vaccine Institute (DHVI) Research Flow Cytometry
392 Shared Resource Facility (Durham, NC). For phenotyping, cryopreserved umbilical cord blood was
393 thawed briefly at 37°C and resuspended in R10 media (RPM1 1640 with glutamine [Gibco] plus 10%
394 heat-inactivated fetal bovine serum [FBS]) with Benzonase (Millipore; 2ul/mL). Re-suspended cord blood
395 was then pelleted at 1500 rpm for 5 minutes. Following pelleting, fetal red blood cells were lysed with ~3
396 mL of RBC lysis buffer for 5 mins then washed with 1X PBS and pelleted at 1500 rpm for 5 mins. CBMCs
397 were then re-suspended and enumerated on a Muse Cell Analyzer before being pelleted at 1500 rpm for
398 5 mins and re-suspended at 2.0×10^7 cells/mL in 1% PBS/BSA. For phenotyping, 5-10 million cells
399 (depending on viable cell count after cryopreservation) were stained with an optimized monoclonal
400 antibody cocktail of fluorescently conjugated antibodies against surface markers for 30 mins at 4°C.
401 Antibodies in the general lineage panel included: CD14 pacific blue (M5E2, Biolegend), CD16 BV570
402 (3G8, Biolegend), CD25 BV605 (BC96, Biolegend), CD56 BV650 (HCD56, Biolegend), NKG2C BV711
403 (134591), CD45 BV786 (HI30, BD Biosciences), CD34 FITC (561, Biolegend), CD19 BB700 (HIB19, BD
404 Biosciences), NKG2A PE (S19004C, Biolegend), CD235a PE-Cy-5 (HIR2, Biolegend), CD3 PE-Texas
405 Red (7D6, ThermoFisher), CD127 PE-Cy7 (A019D5, Biolegend), CD8 APC (RPA-T8, BD Biosciences),
406 HLA-DR AF700 (L243, Biolegend), and CD4 APC-H7 (SK3, BD Biosciences). Antibodies in the T and
407 NK cell panel included: CD3 BV421 (UCHT1, BD Biosciences), CD8 BV570 (RPA-T8, Biolegend), CCR7
408 BV605 (G043H7, Biolegend), CD56 BV650 (HCD56, Biolegend), PD-1 BV785 (EH12.2H7, Biolegend),
409 TCR γ/δ FITC (11F2, BD Biosciences), CD45RA PerCP-Cy5.5 (HI100, Biolegend), NKG2C PE (S19005E,
410 Biolegend), CD57 PE-CF594 (NK-1, BD Biosciences), CD235a PE-Cy5 (HIR2, Biolegend), CD16 PE-
411 Cy7 (3G8, BD Biosciences), and NKG2A PE-Cy5 (HIR2, Biolegend) and CD4 AF700 (L200, BD
412 Biosciences). Cells were then washed with PBS and pelleted at 1500 rpm for 5 mins and resuspended
413 in live/dead Aqua (ThermoFisher) or near IR (Invitrogen) stain and incubated at room temperature for 20

414 mins. Fluorescence minus one (FMO) control tubes were included for CD34, CD16, CD56, CD127, HLA-
415 DR, TCR γ/δ , CCR7, CD45RA, NKG2A, NKG2C, CD57, and PD-1 for downstream manual gating. Single
416 color AbC or ArC beads (Invitrogen) for each antibody and live/dead stain were used as compensation
417 controls. Flow cytometry data was acquired on a FACSAria (BD Biosciences) instrument using FACSDiva
418 (v8.0) and analyzed in FlowJo (v10.8.1).

419

420 **CITRUS analysis**

421 tSNE-CUDA dimensionality reduction and CITRUS (cluster identification, characterization, and
422 regression) analyses (Bruggner *et al.*, 2014) were completed in Cytobank, a cloud-based bioinformatics
423 platform for analyzing high dimensional cytometry data (Beckman Coulter; www.cytobank.org). All
424 samples were pre-gated on live, CD235 negative cells before FCS files before downstream analyses.
425 For the tSNE-CUDA analysis, 400,000 live, CD235- events were sampled per sample FCS file and
426 perplexity was set to 40. For the general lineage panel CITRUS analysis, 50,000 live, CD235- events
427 were sampled per sample FCS file (n=25 CBMCs, total cell events = 1,250,000) and the minimum cluster
428 size was set to 1% of total events. CD3, CD4, CD8, CD127, CD25, CD19, CD56, CD16, NKG2A, NKG2C,
429 HLA-DR, and CD14 marker expression was normalized across all samples then used as channels for
430 clustering. For the T and NK cell panel CITRUS analysis, 75,000 live, CD235- events were sampled per
431 sample FCS file (n=16 CBMCs, total cell events = 1,200,000) and the minimum cluster size was set to
432 1% of total events. CD3, CD4, CD8, CD56, CD16, $\gamma\delta$ TCR, CCR7, CD45RA, PD-1, CD57, NKG2A, and
433 NKG2C marker expression was normalized across all samples then used as channels for clustering.
434 SAM, a correlative association model, was used to identify cell clusters that differed in abundance
435 (significance cut-off FDR $P < 0.01$) between cCMV+ and cCMV- groups.

436

437 **RNA-seq sample preparation and analysis**

438 T and NK cell subsets were FAC-sorted directly into RLT lysis buffer (Qiagen), and total RNA was
439 extracted using the RNeasy Micro Kit (Qiagen Cat. No. 74004). Total CD4+ T, CD8+ T, and NK cells
440 were sorted from 25 unique cord blood samples (n=13 cCMV+, n=12 cCMV-); however, several samples

441 failed RNA quality control and were excluded from downstream transcriptional analyses. CD16-CD8+
442 and CD16+CD8+ T cell subsets were sorted from a total of 16 unique cord blood samples (n=8 cCMV+,
443 n=8 cCMV-), and one sample from the cCMV- group failed QC and was excluded from downstream
444 transcriptional analyses. RNA quality was evaluated by RIN number (minimum cut-off > 8.5) prior to
445 library preparation by the Duke Human Vaccine Institute (DHVI) Sequencing Core Facility. Briefly, full
446 length cDNAs were generated using up to 10ng of total RNA through the SMART-Seq v4 Ultra Low Input
447 Kit for Sequencing (Takara Cat. No. 634891). Total 200pg cDNAs were used to generate the dual index
448 Illumina libraries using Nextera XT DNA Library Prep Kit (Illumina Cat No. FC-131-1096). Sequencing
449 was performed on an Illumina NextSeq 500 sequencer to generate 2 × 76 paired-end reads using TG
450 NextSeq 500/550 High Output kit v2.5 (150 cycles) following the manufacturer's protocol (Illumina, Cat.
451 No. 20024912). The quality of cDNAs and Illumina libraries were assessed on a TapeStation 2200 with
452 the high sensitivity D5000 ScreenTape (Agilent Cat, No. 5067-5592), and their quantity were determined
453 by Qubit 3.0 fluorometer (Thermo Fisher). Gene reads were aligned to the human reference genome
454 GRCh38 using Qiagen CLC genomics (v20). DEseq2 (v1.38.3) was used to normalize count data and
455 perform differential gene expression analysis. Genes were considered differentially expressed based on
456 a 1.2 log₂fold change in gene expression and FDR $P < 0.1$. PCA was performed on rlog-transformed
457 data using the plotPCA function in DESeq2. Volcano plots were generated using the EnhancedVolcano
458 (v1.16.0) package in R. Heatmaps and hierarchical clustering was performed on rlog-normalized
459 DEseq2data using the ComplexHeatmap (2.14.0) package in R. Gene set enrichment analysis of
460 differentially expressed gene ontology (GO) pathways (min 5, max 2000 genes) was performed using
461 iDEP v0.96 (Ge et al., 2018) with a significance cut-off of FDR $P < 0.2$.

462

463 ***Functional immunological assays***

464 Antibody-dependent degranulation of NK and CD8+ T cells was performed as follows. Cord blood was
465 thawed at 37°C, diluted 1:4 in RPMI supplemented with 10% FBS, penicillin, streptomycin, L-glutamine,
466 and gentamicin (complete media) and processed using Ficoll separation. Following separation, the cells
467 were counted and rested overnight at a concentration 2-3 million cells per mL in either complete media

468 or complete media supplemented with 1ng/mL of IL-15. After resting overnight, the cells were counted
469 and resuspended at 5 million/mL. CBMCs in bulk are referred to as “Effector” cells and CEM.NKRs coated
470 with 5 ug/mL BAL gp120 are referred to as “Target” cells. CBMCs were either plated alone (Effector only),
471 with a 10:1 ratio with targets (Effector+Target), and with 1ug/mL of Synagis (Effector+Targets+Synagis)
472 or 1ug/mL a mixture of 4 optimized HIV antibodies (Effector+Target+mAb Mix). The HIV antibody cocktail
473 comprised of 250 ng/mL each of 7B2_AAA, 2G12_AAA, A32_AAA, and CH44_AAA which contain the
474 AAA optimization for Fc mediated activity. All four conditions were plated for 6 hours in the presence of
475 1ug/mL brefeldin (BD GolgiPlug), 1ug/mL Monensin A (BD GolgiStop, and anti-CD107a antibody
476 (Biolegend H4A3). After 6 hours, the cells were washed with DPBS and stained with Live/Dead viability
477 stain (ThermoFischer), then washed and stained for the following surface markers: CD14 V500 (M5E2,
478 BD biosciences), CD19 V500 (HIB19, BD biosciences), CD57 BV711 (QA17A04, Biolegend), CD4
479 BV785 (OKT4, Biolegend), CD45RA FITC (5H9, BD biosciences), CD16 PE (3g8, Biolegend). CCR7 Pe-
480 Cy5 (G043H7, Biolegend), CD8 PerCP Cy5-5 (SK1, Biolegend), CD56 PeCy7 (NCAM16.2, BD
481 biosciences), CD3 APC-Cy7 (SK7, BD biosciences). Next, cells were fixed with CytoFix/CytoPerm (BD
482 Biosciences) then stained for the following intracellular markers: Perforin PacBlue (dg9, Biolegend), IFN γ
483 APC (4S.B3, Biolegend), Granzyme B AF700 (QA16A02, Biolegend) in the presence of Perm/Wash
484 Buffer (BD Biosciences). Samples were acquired on a LSRFortessa II (BD biosciences) using FACSDiva
485 v8.0 software. Frequency of NK and CD8+ T cells expressing granzyme B and perforin were measured
486 in the effector only condition. Percentage change in IFN γ and CD107a were calculated by subtracting
487 the frequencies in the Effector+Target conditions from the antibody conditions. Data was analyzed using
488 FlowJo Version 10.8.

489

490 **Statistical Analysis**

491 All statistical analyses were completed in R (v4.1.1) or GraphPad Prism (v9.1). Frequencies of immune
492 cell populations or normalized gene expression data were compared using Mann-Whitney U/Wilcoxon
493 rank-sum tests for pair-wise comparisons and Kruskal-Wallis one-way ANOVA for comparisons across
494 multiple groups. Statistical significance was defined a priori as $P < 0.05$ with a two-tailed test and FDR

495 correction for multiple comparisons. Specific details on each statistical analysis performed and the exact
496 n are available in the respective figure legends. Additional details on the statistical significance thresholds
497 for the CITRUS and RNA-seq analyses are described in the methods section above. Inclusion and
498 exclusion criteria for the study are described above and outlined in **Supplementary Fig. 1** and
499 randomization for case-control matching was achieved using a random number generator.
500

501 **Author contributions**

502 Conceptualization, ECS, DRN, GF, JP, SRP, KMW; Formal Analysis, ECS, DRN; Methodology, ECS,
503 TDB, CBC, KR, JP, SRP, KMW; Data curation, ECS; Funding acquisition, ECS, CBC, JHH, SRP, KMW;
504 Investigation, ECS, DRN, AN; Project administration, JHH; Resources, DC, KR, JK, CBC; Software, ECS,
505 CBC; Supervision, JP, SRP, KMW; Visualization, ECS, DRN; Writing – original draft, ECS, DRN; Writing
506 – review & editing, ECS, DRN, AN, JHH, DC, TDB, JK, KR, CBC, GF, JP, SRP, KMW.

507 **Acknowledgements:** Thank you to the CCBB donors and staff including Jose Hernandez, Ann Kaestner,
508 and Korrynn Vincent who were instrumental in acquiring the biospecimens and donor clinical information
509 for this study. We also would like to thank Aria Arus-Altuz and Evan Trudeau at the Duke Human Vaccine
510 Institute Flow Cytometry Facility (Durham, NC) for their assistance in panel design and FAC-sorting, and
511 Yue Chen and Bhavna Hora at the Duke Human Vaccine Institute Sequencing Core for their help in with
512 RNA sequencing. This project was supported by NIH NCI 1R21CA242439-01 “Immune Correlates and
513 Mechanisms of Perinatal Cytomegalovirus Infection and Later Life ALL Development” (KMW, SRP), NIH
514 NIAID 1R01AI173333 “Identifying and modeling immune correlates of protection against congenital CMV
515 transmission after primary maternal infection” (SRP), NIH NIAID R01AI145828 “Innate immune signaling
516 in placental antiviral defenses” (CBC), the Triangle Center for Evolutionary Medicine (TriCEM) graduate
517 student research award “Human cytomegalovirus and host B cell evolution across the lifespan” to ECS
518 and the Translating Duke Health Children’s Health and Discovery Initiative. The funders had no role in
519 study design, data collection and analysis, decision to publish, or preparation of the manuscript.

520

521 **Declaration of interests:** We have read the journal's policy and the authors of this manuscript have the
522 following financial conflict of interest to disclose: JK is a consultant for Matrix Capital Management Fund,
523 the medical director of the Carolinas Cord Blood Bank, the medical director of the Cryo-Cell Cord Blood
524 Bank, and receives royalties from a licensing agreement between Duke and Cryo-Cell and Duke and
525 Sinocell for data and regulatory packages regarding manufacturing and therapeutic use of cord blood
526 and cord tissue cells in patients with cerebral palsy, hypoxic ischemic encephalopathy, stroke, and
527 autism. SRP is a consultant for Moderna, Merck, Pfizer, GSK, Dynavax, and Hoopika CMV vaccine
528 programs and leads sponsored research programs with Moderna, Merck, and Dynavax. She also serves
529 on the board of the National CMV Foundation and as an educator on CMV for Medscape. KMW has a
530 sponsored research project from Moderna on immune correlates of congenital CMV infection. The other
531 authors have declared that no other conflict of interest.
532

533 References

- 534 Almanzar, G., Schwaiger, S., Jenewein, B., Keller, M., Herndler-Brandstetter, D., Wurzner, R.,
535 Schonitzer, D., and Grubeck-Loebenstein, B. (2005). Long-term cytomegalovirus infection leads to
536 significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an
537 imbalance in the cytokine production profile in elderly persons. *Journal of virology* 79, 3675-3683.
538 10.1128/jvi.79.6.3675-3683.2005.
- 539 Antoine, P., Olislagers, V., Huygens, A., Lecomte, S., Liesnard, C., Donner, C., and Marchant, A.
540 (2012). Functional exhaustion of CD4+ T lymphocytes during primary cytomegalovirus infection.
541 *Journal of immunology* (Baltimore, Md. : 1950) 189, 2665-2672. 10.4049/jimmunol.1101165.
- 542 Björkström, N.K., Gonzalez, V.D., Malmberg, K.J., Falconer, K., Alaeus, A., Nowak, G., Jorns, C.,
543 Ericzon, B.G., Weiland, O., Sandberg, J.K., and Ljunggren, H.G. (2008). Elevated numbers of Fc
544 gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus
545 infection. *Journal of immunology* (Baltimore, Md. : 1950) 181, 4219-4228.
546 10.4049/jimmunol.181.6.4219.
- 547 Boppana, S.B., Ross, S.A., and Fowler, K.B. (2013). Congenital cytomegalovirus infection: clinical
548 outcome. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*
549 *America* 57 Suppl 4, S178-181. 10.1093/cid/cit629.
- 550 Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C.J., Furman, D., Shen-Orr, S., Dekker, C.L.,
551 Swan, G.E., Butte, A.J., et al. (2015). Variation in the human immune system is largely driven by non-
552 heritable influences. *Cell* 160, 37-47. 10.1016/j.cell.2014.12.020.
- 553 Bruggner, R.V., Bodenmiller, B., Dill, D.L., Tibshirani, R.J., and Nolan, G.P. (2014). Automated
554 identification of stratifying signatures in cellular subpopulations. *Proceedings of the National Academy*
555 *of Sciences of the United States of America* 111, E2770-2777. 10.1073/pnas.1408792111.
- 556 Cadwell, K. (2015). The virome in host health and disease. *Immunity* 42, 805-813.
557 10.1016/j.immuni.2015.05.003.
- 558 Chan, D.M., Rao, R., Huang, F., and Canny, J.F. (2019). GPU accelerated t-distributed stochastic
559 neighbor embedding. *Journal of Parallel and Distributed Computing* 131, 1-13.
560 <https://doi.org/10.1016/j.jpdc.2019.04.008>.
- 561 Choi, S.J., Koh, J.Y., Rha, M.S., Seo, I.H., Lee, H., Jeong, S., Park, S.H., and Shin, E.C. (2023).
562 KIR(+)/CD8(+) and NKG2A(+)/CD8(+) T cells are distinct innate-like populations in humans. *Cell reports*
563 42, 112236. 10.1016/j.celrep.2023.112236.
- 564 Chung, A.W., Rollman, E., Center, R.J., Kent, S.J., and Stratov, I. (2009). Rapid Degranulation of NK
565 Cells following Activation by HIV-Specific Antibodies¹. *The Journal of Immunology* 182, 1202-1210.
566 10.4049/jimmunol.182.2.1202.
- 567 Clémenceau, B., Vivien, R., Berthomé, M., Robillard, N., Garand, R., Gallot, G., Volland, S., and Vié, H.
568 (2008). Effector memory alpha beta T lymphocytes can express Fc gamma RIIIA and mediate antibody-
569 dependent cellular cytotoxicity. *Journal of immunology* (Baltimore, Md. : 1950) 180, 5327-5334.
570 10.4049/jimmunol.180.8.5327.
- 571 Davis, M.M., and Brodin, P. (2018). Rebooting Human Immunology. *Annual review of immunology* 36,
572 843-864. 10.1146/annurev-immunol-042617-053206.

- 573 Forconi, C.S., Cosgrove, C.P., Saikumar-Lakshmi, P., Nixon, C.E., Foley, J., Ong'echa, J.M., Otieno,
574 J.A., Alter, G., Munz, C., and Moormann, A.M. (2018). Poorly cytotoxic terminally differentiated
575 CD56(neg)CD16(pos) NK cells accumulate in Kenyan children with Burkitt lymphomas. *Blood Adv* 2,
576 1101-1114. 10.1182/bloodadvances.2017015404.
- 577 Forconi, C.S., Oduor, C.I., Oluoch, P.O., Ong'echa, J.M., Münz, C., Bailey, J.A., and Moormann, A.M.
578 (2020). A New Hope for CD56(neg)CD16(pos) NK Cells as Unconventional Cytotoxic Mediators: An
579 Adaptation to Chronic Diseases. *Front Cell Infect Microbiol* 10, 162. 10.3389/fcimb.2020.00162.
- 580 Fouda, G.G., Martinez, D.R., Swamy, G.K., and Permar, S.R. (2018). The Impact of IgG transplacental
581 transfer on early life immunity. *Immunohorizons* 2, 14-25. 10.4049/immunohorizons.1700057.
- 582 Furman, D., Jovic, V., Sharma, S., Shen-Orr, S.S., Angel, C.J., Onengut-Gumuscu, S., Kidd, B.A.,
583 Maecker, H.T., Concannon, P., Dekker, C.L., et al. (2015). Cytomegalovirus infection enhances the
584 immune response to influenza. *Science translational medicine* 7, 281ra243.
585 10.1126/scitranslmed.aaa2293.
- 586 Galindo-Albarrán, A.O., López-Portales, O.H., Gutiérrez-Reyna, D.Y., Rodríguez-Jorge, O., Sánchez-
587 Villanueva, J.A., Ramírez-Pliego, O., Bergon, A., Loriod, B., Holota, H., Imbert, J., et al. (2016). CD8(+)
588 T Cells from Human Neonates Are Biased toward an Innate Immune Response. *Cell reports* 17, 2151-
589 2160. 10.1016/j.celrep.2016.10.056.
- 590 Ge, S.X., Son, E.W., and Yao, R. (2018). iDEP: an integrated web application for differential expression
591 and pathway analysis of RNA-Seq data. *BMC bioinformatics* 19, 534. 10.1186/s12859-018-2486-6.
- 592 Guma, M., Angulo, A., Vilches, C., Gomez-Lozano, N., Malats, N., and Lopez-Botet, M. (2004). Imprint
593 of human cytomegalovirus infection on the NK cell receptor repertoire. *Blood* 104, 3664-3671.
594 10.1182/blood-2004-05-2058.
- 595 Guma, M., Budt, M., Saez, A., Brckalo, T., Hengel, H., Angulo, A., and Lopez-Botet, M. (2006).
596 Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts.
597 *Blood* 107, 3624-3631. 10.1182/blood-2005-09-3682.
- 598 Huygens, A., Dauby, N., Vermijlen, D., and Marchant, A. (2014). Immunity to cytomegalovirus in early
599 life. *Frontiers in immunology* 5, 552. 10.3389/fimmu.2014.00552.
- 600 Huygens, A., Lecomte, S., Tackoen, M., Olislagers, V., Delmarcelle, Y., Burny, W., Van Rysselberge,
601 M., Liesnard, C., Larsen, M., Appay, V., et al. (2015). Functional Exhaustion Limits CD4+ and CD8+ T-
602 Cell Responses to Congenital Cytomegalovirus Infection. *The Journal of infectious diseases* 212, 484-
603 494. 10.1093/infdis/jiv071.
- 604 Jennewein, M.F., Abu-Raya, B., Jiang, Y., Alter, G., and Marchant, A. (2017). Transfer of maternal
605 immunity and programming of the newborn immune system. *Seminars in immunopathology* 39, 605-
606 613. 10.1007/s00281-017-0653-x.
- 607 Jennewein, M.F., Goldfarb, I., Dolatshahi, S., Cosgrove, C., Noelette, F.J., Krykbaeva, M., Das, J.,
608 Sarkar, A., Gorman, M.J., Fischinger, S., et al. (2019). Fc Glycan-Mediated Regulation of Placental
609 Antibody Transfer. *Cell* 178, 202-215.e214. 10.1016/j.cell.2019.05.044.
- 610 Koh, J.Y., Kim, D.U., Moon, B.H., and Shin, E.C. (2023). Human CD8(+) T-Cell Populations That
611 Express Natural Killer Receptors. *Immune Netw* 23, e8. 10.4110/in.2023.23.e8.

- 612 Kollmann, T.R., Kampmann, B., Mazmanian, S.K., Marchant, A., and Levy, O. (2017). Protecting the
613 Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny. *Immunity* 46,
614 350-363. 10.1016/j.immuni.2017.03.009.
- 615 Lee, J., Zhang, T., Hwang, I., Kim, A., Nitschke, L., Kim, M., Scott, J.M., Kamimura, Y., Lanier, L.L., and
616 Kim, S. (2015). Epigenetic modification and antibody-dependent expansion of memory-like NK cells in
617 human cytomegalovirus-infected individuals. *Immunity* 42, 431-442. 10.1016/j.immuni.2015.02.013.
- 618 Malarkannan, S. (2020). NKG7 makes a better killer. *Nature immunology* 21, 1139-1140.
619 10.1038/s41590-020-0767-5.
- 620 Marchant, A., Appay, V., Van Der Sande, M., Dulphy, N., Liesnard, C., Kidd, M., Kaye, S., Ojuola, O.,
621 Gillespie, G.M., Vargas Cuero, A.L., et al. (2003). Mature CD8(+) T lymphocyte response to viral
622 infection during fetal life. *The Journal of clinical investigation* 111, 1747-1755. 10.1172/jci17470.
- 623 Martinez, D.R., Fong, Y., Li, S.H., Yang, F., Jennewein, M.F., Weiner, J.A., Harrell, E.A., Mangold, J.F.,
624 Goswami, R., Seage, G.R., 3rd, et al. (2019). Fc Characteristics Mediate Selective Placental Transfer
625 of IgG in HIV-Infected Women. *Cell* 178, 190-201.e111. 10.1016/j.cell.2019.05.046.
- 626 Mazzarino, P., Pietra, G., Vacca, P., Falco, M., Colau, D., Coulie, P., Moretta, L., and Mingari, M.C.
627 (2005). Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells
628 in an HLA-E-restricted fashion. *European journal of immunology* 35, 3240-3247.
629 10.1002/eji.200535343.
- 630 Monsivais-Urenda, A., Noyola-Cherpitel, D., Hernandez-Salinas, A., Garcia-Sepulveda, C., Romo, N.,
631 Baranda, L., Lopez-Botet, M., and Gonzalez-Amaro, R. (2010). Influence of human cytomegalovirus
632 infection on the NK cell receptor repertoire in children. *European journal of immunology* 40, 1418-1427.
633 10.1002/eji.200939898.
- 634 Naluyima, P., Lal, K.G., Costanzo, M.C., Kijak, G.H., Gonzalez, V.D., Blom, K., Eller, L.A., Creegan, M.,
635 Hong, T., Kim, D., et al. (2019). Terminal Effector CD8 T Cells Defined by an IKZF2(+)IL-7R(-)
636 Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific
637 Antibody-Dependent Cellular Cytotoxicity. *Journal of immunology (Baltimore, Md. : 1950)* 203, 2210-
638 2221. 10.4049/jimmunol.1900422.
- 639 Ng, S.S., De Labastida Rivera, F., Yan, J., Corvino, D., Das, I., Zhang, P., Kuns, R., Chauhan, S.B.,
640 Hou, J., Li, X.Y., et al. (2020). The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis
641 and inflammation. *Nature immunology* 21, 1205-1218. 10.1038/s41590-020-0758-6.
- 642 Noyola, D.E., Fortuny, C., Muntasell, A., Noguera-Julian, A., Munoz-Almagro, C., Alarcon, A., Juncosa,
643 T., Moraru, M., Vilches, C., and Lopez-Botet, M. (2012). Influence of congenital human cytomegalovirus
644 infection and the NKG2C genotype on NK-cell subset distribution in children. *European journal of*
645 *immunology* 42, 3256-3266. 10.1002/eji.201242752.
- 646 Phaahla, N.G., Lassaunière, R., Da Costa Dias, B., Waja, Z., Martinson, N.A., and Tiemessen, C.T.
647 (2019). Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional
648 Consequence of the FcγRIIIa-F158V Variant. *Frontiers in immunology* 10, 735.
649 10.3389/fimmu.2019.00735.
- 650 Pietra, G., Romagnani, C., Mazzarino, P., Falco, M., Millo, E., Moretta, A., Moretta, L., and Mingari,
651 M.C. (2003). HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+
652 cytolytic T lymphocytes. *Proceedings of the National Academy of Sciences of the United States of*
653 *America* 100, 10896-10901. 10.1073/pnas.1834449100.

- 654 Pollara, J., Edwards, R.W., Jha, S., Lam, C.K., Liu, L., Diedrich, G., Nordstrom, J.L., Huffman, T.,
655 Pickeral, J.A., Denny, T.N., et al. (2020). Redirection of Cord Blood T Cells and Natural Killer Cells for
656 Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. *Frontiers in*
657 *immunology* 11, 713. 10.3389/fimmu.2020.00713.
- 658 Remmerswaal, E.B.M., Hombrink, P., Nota, B., Pircher, H., Ten Berge, I.J.M., van Lier, R.A.W., and
659 van Aalderen, M.C. (2019). Expression of IL-7R α and KLRG1 defines functionally distinct CD8(+) T-cell
660 populations in humans. *European journal of immunology* 49, 694-708. 10.1002/eji.201847897.
- 661 Rolle, A., and Brodin, P. (2016). Immune Adaptation to Environmental Influence: The Case of NK Cells
662 and HCMV. *Trends in immunology* 37, 233-243. 10.1016/j.it.2016.01.005.
- 663 Rückert, T., Lareau, C.A., Mashreghi, M.F., Ludwig, L.S., and Romagnani, C. (2022). Clonal expansion
664 and epigenetic inheritance of long-lasting NK cell memory. *Nature immunology* 23, 1551-1563.
665 10.1038/s41590-022-01327-7.
- 666 Schlums, H., Cichocki, F., Tesi, B., Theorell, J., Beziat, V., Holmes, T.D., Han, H., Chiang, S.C., Foley,
667 B., Mattsson, K., et al. (2015). Cytomegalovirus infection drives adaptive epigenetic diversification of
668 NK cells with altered signaling and effector function. *Immunity* 42, 443-456.
669 10.1016/j.immuni.2015.02.008.
- 670 Semmes, E.C., Chen, J.L., Goswami, R., Burt, T.D., Permar, S.R., and Fouda, G.G. (2020a).
671 Understanding Early-Life Adaptive Immunity to Guide Interventions for Pediatric Health. *Frontiers in*
672 *immunology* 11, 595297. 10.3389/fimmu.2020.595297.
- 673 Semmes, E.C., Hurst, J.H., Walsh, K.M., and Permar, S.R. (2020b). Cytomegalovirus as an
674 immunomodulator across the lifespan. *Curr Opin Virol* 44, 112-120. 10.1016/j.coviro.2020.07.013.
- 675 Semmes, E.C., Miller, I.G., Rodgers, N., Phan, C.T., Hurst, J.H., Walsh, K.M., Stanton, R.J., Pollara, J.,
676 and Permar, S.R. (2023). ADCC-activating antibodies correlate with decreased risk of congenital
677 human cytomegalovirus transmission. *JCI Insight* 8. 10.1172/jci.insight.167768.
- 678 Semmes, E.C., Miller, I.G., Wimberly, C.E., Phan, C.T., Jenks, J.A., Harnois, M.J., Berendam, S.J.,
679 Webster, H., Hurst, J.H., Kurtzberg, J., et al. (2022). Maternal Fc-mediated non-neutralizing antibody
680 responses correlate with protection against congenital human cytomegalovirus infection. *The Journal of*
681 *clinical investigation*. 10.1172/JCI156827.
- 682 Semmes, E.C., and Permar, S.R. (2022). Human cytomegalovirus infection primes fetal NK cells for Fc-
683 mediated anti-viral defense. *The Journal of infectious diseases*. 10.1093/infdis/jiac308.
- 684 Sottile, R., Panjwani, M.K., Lau, C.M., Daniyan, A.F., Tanaka, K., Barker, J.N., Brentjens, R.J., Sun,
685 J.C., Le Ludec, J.B., and Hsu, K.C. (2021). Human cytomegalovirus expands a CD8(+) T cell
686 population with loss of BCL11B expression and gain of NK cell identity. *Sci Immunol* 6, eabe6968.
687 10.1126/sciimmunol.abe6968.
- 688 Sylwester, A.W., Mitchell, B.L., Edgar, J.B., Taormina, C., Pelte, C., Ruchti, F., Sleath, P.R., Grabstein,
689 K.H., Hosken, N.A., Kern, F., et al. (2005). Broadly targeted human cytomegalovirus-specific CD4+ and
690 CD8+ T cells dominate the memory compartments of exposed subjects. *The Journal of experimental*
691 *medicine* 202, 673-685. 10.1084/jem.20050882.
- 692 Thomas, A.S., Coote, C., Moreau, Y., Isaac, J.E., Ewing, A.C., Kourtis, A.P., and Sagar, M. (2022).
693 Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child
694 transmission. *JCI Insight* 7. 10.1172/jci.insight.159435.

- 695 Ty, M., Sun, S., Callaway, P.C., Rek, J., Press, K.D., van der Ploeg, K., Nideffer, J., Hu, Z., Klemm, S.,
696 Greenleaf, W., et al. (2023). Malaria-driven expansion of adaptive-like functional CD56-negative NK
697 cells correlates with clinical immunity to malaria. *Science translational medicine* 15, eadd9012.
698 [10.1126/scitranslmed.add9012](https://doi.org/10.1126/scitranslmed.add9012).
- 699 Vaaben, A.V., Levan, J., Nguyen, C.B.T., Callaway, P.C., Prah, M., Warriar, L., Nankya, F., Musinguzi,
700 K., Kakuru, A., Muhindo, M.K., et al. (2022). In Utero Activation of Natural Killer Cells in Congenital
701 Cytomegalovirus Infection. *The Journal of infectious diseases* 226, 566-575. [10.1093/infdis/jiac307](https://doi.org/10.1093/infdis/jiac307).
- 702 Vermijlen, D., Brouwer, M., Donner, C., Liesnard, C., Tackoen, M., Van Rysselberge, M., Twite, N.,
703 Goldman, M., Marchant, A., and Willems, F. (2010). Human cytomegalovirus elicits fetal gammadelta T
704 cell responses in utero. *The Journal of experimental medicine* 207, 807-821. [10.1084/jem.20090348](https://doi.org/10.1084/jem.20090348).
- 705 Zuhair, M., Smit, G.S.A., Wallis, G., Jabbar, F., Smith, C., Devleeschauwer, B., and Griffiths, P.
706 (2019). Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-
707 analysis. *Reviews in medical virology* 29, e2034. [10.1002/rmv.2034](https://doi.org/10.1002/rmv.2034).
- 708




Figure 1. Umbilical cord blood donor cell phenotyping highlights distinct immune landscape in cCMV-infected versus uninfected neonates. Flow cytometry analysis of umbilical cord blood from n=59 cCMV-infected (cCMV+, red circles) and n=135 cCMV-uninfected (cCMV-, blue triangles) neonates was performed by the CCBB at the time of donation. (A-G) Frequencies and total immune cell counts from cord blood graft characterization. (H-I) Principal components analysis (PCA) of graft characterization data including 18 immune cell parameters from CCBB database. (H) Scatterplot of PC1 and PC2. (I) Immune cell parameter loading variables ordered by magnitude of contribution to PC1. FDR-corrected *P* values for Mann-Whitney U test. *****P* < 0.0001. **P* < 0.05.




Figure 2. CD16/FcγRIII⁺CD56^{neg} and NKG2C⁺ NK cells expand in cord blood from cCMV-infected versus cCMV-uninfected neonates. NK cell immunophenotypes and transcriptional profiles were compared in umbilical cord blood from cCMV-infected (cCMV+, red circles) versus cCMV-uninfected (cCMV-, blue diamonds) neonates. (A) NK cell gating strategy. (B) Frequencies of NK cell subsets in cCMV+ (n=21) versus cCMV- (n=20) neonates. (C) Frequency of total NK cells and NK cell subsets expressing CD57 in cCMV+ (n=8) versus cCMV- (n=8) neonates. (D-E) Frequency of total NK cells and NK cell subsets expressing (D) NKG2A and (E) NKG2C in cCMV+ (n=21) versus cCMV- (n=20) neonates. (F) Volcano plot demonstrating differentially expressed genes in FAC-sorted total NK cells from cCMV+ (n=13) and cCMV- (n=12) neonates. Significance was set at *P* < 0.01 and log₂foldchange +/- 1.2. Red circles indicate genes enriched in cCMV+ NK cells, blue circles indicate genes enriched in cCMV- NK cells, and grey circles indicate genes whose expression did not differ significantly between groups. (G) Heatmap of top 23 enriched genes (FDR *P* < 0.1, log₂foldchange > 1.2) in NK cells from cCMV+ (n=13) versus cCMV- (n=12) neonates. Z-score shows gene expression based on rlog-transformed data. FDR-corrected *P* values for Mann-Whitney U test. **P* < 0.05, ***P* < 0.01, ****P* < 0.001.




Figure 3. CD8+ T cells upregulate cytotoxic molecules and NK cell associated genes in cord blood from cCMV-infected versus uninfected neonates. (A-B) CD8+ T cell immunophenotypes were compared in umbilical cord blood from cCMV-infected (cCMV+, red circles) versus cCMV-uninfected (cCMV-, blue diamonds) neonates. (A) Frequency of total, naïve, central memory (Tcm), effector memory (Tem), and terminally differentiated effector memory cells re-expressing CD45RA+ (Temra) CD8+ T cells in cord blood from cCMV+ (n=21 total) versus cCMV- neonates (n=20 total). (B) Frequency of total CD8+ T cells expressing HLA-DR, CD57, and PD-1. (C) Volcano plot demonstrating differentially expressed genes in FAC-sorted total CD8+ T cells from cCMV+ (n=13) and cCMV- (n=11) neonates. Significance was set at $P < 0.01$ and $\log_2\text{foldchange} \pm 1.2$. Red circles indicate genes enriched in cCMV+ CD8+ T cells, blue circles indicate genes enriched in cCMV- CD8+ T cells, and grey circles indicate genes whose expression did not differ significantly between groups. (D) Heatmap of top 40 enriched genes (FDR $P < 0.1$, $\log_2\text{foldchange} > 3.0$, mean count > 500) in CD8+ T cells from cCMV+ (n=13) versus cCMV- (n=11) neonates. Z-score shows gene expression based on rlog-transformed data. (E-F) Selected gene expression levels in CD8+ T cells from cCMV+ (n=13) versus cCMV- (n=11) neonates including genes encoding (E) T and NK cell cytotoxic molecules and (F) NK cell associated genes. FDR-corrected P values for Mann-Whitney U test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Figure 4. CD8+ T cells expressing NK cell receptors FcγRIII/CD16 and NKG2A/C expand in cord blood from cCMV-infected versus uninfected neonates. (A-D) Cluster identification, characterization, and regression (CITRUS) analysis of flow cytometry data was used to identify immune cell populations i.e., clusters with differing abundance in cord blood from cCMV-infected (n=13) versus cCMV-uninfected (n=12) neonates. (A) t-SNE-CUDA dimensionality reduction of flow cytometry data prior to CITRUS analysis. (B) CITRUS cluster map of 1,250,000 live, CD235a-singlet events (50,000 events/sample, minimum cluster size 1%) with ellipses indicating clusters that differed significantly (FDR $P < 0.01$) between cCMV+ and cCMV- groups. Clusters colored by immune cell lineage including CD8+ T cells (purple), CD4+ T cells (red), NK cells (green), B cells (yellow), monocytes/macrophages (MO/Mφ; orange) and dendritic cells (DCs; blue) based on marker expression in Supplementary Fig 4. (C-D) Select clusters (arrows in panel B) of CD8+ T cells expressing NK cell markers. Dot plots indicate cluster abundance in cCMV+ (red circles) versus cCMV- (blue circles) neonates. Histograms indicate fluorescent marker expression of select cluster (red) relative to background expression (blue). (E) Gating strategy to identify CD8+ T cells expressing NK cell markers. (F) Frequency of FcγRIII/CD16 and NKG2A/C expression on total CD8+ T cells from cCMV+ (red circles, n=21) versus cCMV- (blue diamonds, n=20) neonates. FDR-corrected P values for Mann-Whitney U test. *** $P < 0.001$.




Figure 5. FcγRIII+ CD8+ T (FcRT) cells in cord blood from cCMV-infected neonates are a heterogeneous population expressing activation and terminal differentiation markers. (A-B) Cluster identification, characterization, and regression (CITRUS) analysis of flow cytometry data was used to identify immune cell populations i.e., clusters with differing abundance in cord blood from cCMV-infected (n=8) versus cCMV-uninfected (n=8) neonates. (A) CITRUS cluster map of 1,125,000 live, CD235a- singlet events (75,000 events/sample, minimum cluster size 1%) with ellipses indicating clusters that differed significantly (FDR $P < 0.01$) between cCMV-infected and uninfected groups. Clusters colored by immune cell lineage including CD8+ T cells (purple = FcγRIII-, plum = FcγRIII+), CD4+ T cells (red), NK cells (green), and non-T/NK cells (yellow, aqua) based on marker expression in Supplementary Fig 5. (B) Select clusters (indicated by arrows in panel A) of CD8+ T cells expressing NK cell associated markers. Dot plots indicate cluster abundance in cord blood from cCMV+ (red circles, n=13) versus cCMV- (blue circles, n=12) neonates. Histograms indicate fluorescent marker expression of select cluster (red) relative to background expression (blue). (C-E) Immunophenotypes of FcγRIII+ (plum) and FcγRIII- (cCMV+: purple; cCMV-: blue) CD8+ T cells from cCMV+ (circles, n=8) and cCMV- (diamonds, n=7) neonates. (C) Frequency of γδ T cell receptor expression. (D) Frequency of naïve, central memory (Tcm), effector memory (Tem), and terminally differentiated effector memory cells re-expressing CD45RA+ (Temra) phenotype based on CD45RA and CCR7. Frequency of subsets expressing CD57 or PD-1. (E) Frequency of NKG2A and NKG2C expression. P values for Kruskal-Wallis test * $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$.




Figure 6. FcγRIII+CD8+ T cells (FcRT) in cord blood from cCMV-infected neonates upregulate a NK cell-like antibody effector transcriptional program. (A-E) Transcriptome analysis of FAC-sorted FcγRIII+ and FcγRIII- CD8+ T cells from cCMV-infected (n=8) and cCMV-uninfected (n=7) neonates. (A) Volcano plot demonstrating differentially expressed genes in FcγRIII+ versus FcγRIII- CD8+ T cells. Significance was set at $P < 0.01$ and $\log_2\text{foldchange} \pm 1.2$. Plum circles indicate genes enriched in FcγRIII+ CD8+ T cells (cCMV+ only), blue circles indicate genes enriched in FcγRIII- CD8+ T cells (cCMV- only), and grey circles indicate genes whose expression did not differ significantly between groups. (B) Selected gene expression levels in FcγRIII+ and FcγRIII- CD8+ T cells. (C) Principal components analysis (PCA) of top 500 differentially expressed genes in FcγRIII+ versus FcγRIII- CD8+ T cells. (D-E) Heatmaps of differentially expressed genes in FcγRIII+ and FcγRIII- CD8+ T cells. Z-score shows gene expression based on log-transformed data. (D) Heatmap of top 25 PC1 loading genes. (E) Heatmap of NK cell identity genes. P values for Kruskal-Wallis test **** $P < 0.001$ **** $P < 0.001$.




Figure 7. FcγRIII+ CD8+ T (FcRT) cells in cord blood from cCMV-infected neonates acquire an NK-like transcriptional profile. (A-C) Transcriptome analysis of FAC-sorted FcγRIII- CD8+ T cells, FcγRIII+ CD8+ T cells, and NK cells from cCMV-infected and uninfected neonates. (A) Principal components analysis (PCA) of top 500 differentially expressed genes in FAC-sorted CD8+ T and NK cells. (B-D) Gene expression levels of (B) cytotoxic molecules and (C) FcγR genes. P values for Kruskal-Wallis test **** $P < 0.001$.




Figure 8. Cord blood NK and FcγRIII+CD8⁺ T (FcRT) cells produce IFNγ and degranulate against antibody-opsionized target cells (A-H) Degranulation (CD107a positivity) and IFNγ production following antibody stimulation with anti-RSV IgG (non-specific antibody) or anti-HIV IgG (target cell specific antibody) were measured as markers of antibody-dependent cellular cytotoxic (ADCC) responses in cord blood NK and CD8⁺ T cells from cCMV-infected (n=3 circles) and uninfected (n=3 diamonds) infants. (A) Gating strategy to identify NK cells, FcγRIII+CD8⁺ T cells, and FcγRIII-CD8⁺ T cells. (B) Gating strategy to quantify granzyme B and perforin expression. Percentage of cell population co-expressing granzyme B and perforin at baseline (based on intracellular cytokine staining). (C-D) NK cell degranulation and IFNγ production following antibody stimulation with and without IL-15 pretreatment in cCMV+ (light green circles) and cCMV- (dark green diamonds) infants. (E-F) CD8⁺ T cell degranulation (CD107a) following antibody stimulation with and without IL-15 pretreatment. (G-H) CD8⁺ T cell IFNγ production following antibody stimulation with and without IL-15 pretreatment. *P* values for Kruskal-Wallis test **P* < 0.05 ****P* < 0.001.